Donoghue Forlines’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-29,649
| Closed | -$3.57M | – | 144 |
|
|
2026
Q1 | $3.57M | Buy |
29,649
+14,417
| +95% | +$1.66M | 0.99% | 18 |
|
|
2025
Q4 | $1.6M | Sell |
15,232
-2,467
| -14% | -$232K | 0.5% | 60 |
|
|
2025
Q3 | $1.49M | Sell |
17,699
-642
| -4% | -$52.9K | 0.46% | 83 |
|
|
2025
Q2 | $1.45M | Buy |
18,341
+2,755
| +18% | +$219K | 0.41% | 89 |
|
|
2025
Q1 | $1.4M | Buy |
+15,586
| New | +$1.46M | 0.44% | 100 |
|
|
2024
Q3 | – | Sell |
-15,389
| Closed | -$1.91M | – | 265 |
|
|
2024
Q2 | $1.91M | Buy |
15,389
+17
| +0.1% | +$2.19K | 0.54% | 33 |
|
|
2024
Q1 | $2.03M | Buy |
15,372
+626
| +4% | +$77.2K | 0.58% | 34 |
|
|
2023
Q4 | $1.61M | Sell |
14,746
-939
| -6% | -$97.5K | 0.5% | 40 |
|
|
2023
Q3 | $1.61M | Buy |
15,685
+1,253
| +9% | +$135K | 0.57% | 32 |
|
|
2023
Q2 | $1.67M | Sell |
14,432
-5,916
| -29% | -$672K | 0.52% | 36 |
|
|
2023
Q1 | $2.16M | Sell |
20,348
-5,811
| -22% | -$627K | 0.78% | 17 |
|
|
2022
Q4 | $2.9M | Buy |
26,159
+12,654
| +94% | +$1.29M | 1.03% | 14 |
|
|
2022
Q3 | $1.16M | Sell |
13,505
-7,298
| -35% | -$651K | 0.42% | 23 |
|
|
2022
Q2 | $1.9M | Sell |
20,803
-2,874
| -12% | -$255K | 0.5% | 28 |
|
|
2022
Q1 | $1.94M | Sell |
23,677
-6,293
| -21% | -$496K | 0.42% | 45 |
|
|
2021
Q4 | $2.3M | Buy |
+29,970
| New | +$2.39M | 0.39% | 46 |
|
|
2020
Q4 | – | Sell |
-14,708
| Closed | -$1.16M | – | 281 |
|
|
2020
Q3 | $1.16M | Buy |
+14,708
| New | +$1.15M | 0.32% | 94 |
|
|
2020
Q2 | – | Sell |
-10,388
| Closed | -$763K | – | 86 |
|
|
2020
Q1 | $763K | Sell |
10,388
-28,171
| -73% | -$2.21M | 0.17% | 23 |
|
|
2019
Q4 | $3.35M | Buy |
+38,559
| New | +$3.17M | 0.52% | 44 |
|
|
2018
Q4 | – | Sell |
-201,740
| Closed | -$13.7M | – | 104 |
|
|
2018
Q3 | $13.7M | Sell |
201,740
-68,419
| -25% | -$4.36M | 1.07% | 36 |
|
|
2018
Q2 | $15.6M | Sell |
270,159
-69,944
| -21% | -$3.95M | 1.29% | 39 |
|
|
2018
Q1 | $17.7M | Buy |
340,103
+4,505
| +1% | +$243K | 1.53% | 18 |
|
|
2017
Q4 | $18M | Buy |
335,598
+72,126
| +27% | +$4M | 1.36% | 32 |
|
|
2017
Q3 | $16.1M | Buy |
263,472
+1,354
| +0.5% | +$82.1K | 1.7% | 39 |
|
|
2017
Q2 | $16M | Buy |
+262,118
| New | +$16M | 1.82% | 28 |
|
Other funds holding MRK
Donoghue Forlines's MRK Position: Q2 2026 in Review
Donoghue Forlines sold out of Merck (MRK) in Q2 2026, closing a stake of 29,649 shares — an estimated $3.57M sold.
Donoghue Forlines first reported a position in MRK in Q2 2017 and held it in 25 quarters. The position peaked at $18M in Q4 2017. 3,841 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Donoghue Forlines reported no remaining Merck position as of Q2 2026 after selling out during the quarter.
- Donoghue Forlines sold 29,649 Merck shares in Q2 2026, an estimated $3.57M.
- Donoghue Forlines first reported a position in Merck in Q2 2017 and held it in 25 quarters.
- Donoghue Forlines's Merck position peaked at $18M in Q4 2017.
- 3,841 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Donoghue Forlines's 13F filing for Q2 2026, filed 7 Aug 2026.